A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit

DSpace Repository

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit

Author: Anastasopoulou, Eleftheria A.; Voutsas, Ioannis F.; Keramitsoglou, Theodora; Gouttefangeas, Cecile; Kalbacher, Hubert; Thanos, Anastasios; Papamichail, Michael; Perez, Sonia A.; Baxevanis, Constantin N.
Tübinger Autor(en):
Gouttefangeas, Cécile
Kalbacher, Hubert
Published in: Cancer Immunology Immunotherapy (2015), Bd. 64, H. 9, S. 1123-1136
Verlagsangabe: Springer
Language: English
Full text: http://dx.doi.org/10.1007/s00262-015-1717-1
ISSN: 0340-7004
DDC Classifikation: 610 - Medicine and health
570 - Life sciences; biology
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)